Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No one wants to hit the bid anymore? Comon.
Turns out I like the universe more than money. Oh, and I'll be watching. Don't see why this wouldn't grow as more people process what CBIS is doing.
At the end of the day, the stock being up is all that matters :D~
Funny it seems like a r/s wouldn't be very conducive to the officers' compensation package. More like a SBB.
Neither of the officers or directors beneficially owns
the Company’s securities, although their compensation
agreements provide that they may purchase certain
stock in the event they bring the Company to sales
about $19,000,000.00 per year with at least 20% of
sales resulting in profit within three years. In that
event, the officers could purchase, at $.12 per common
share, up to 8 percent of the Company’s common stock.
In addition, they could purchase up to 3.9% of the
preferred stock in exchange for $350,000.00 pro-rated
depending on the percentage they wish to own.
Interesting read on skin cancer. Seems like CBIS' product blows away the competition and I had no idea the market was this large. Billions could be made on this product alone lol
MOUNTAIN VIEW, Calif. - July 11, 2011 - Globally, a 10 percent decrease in the stratospheric ozone is expected to cause 300,000 additional nonmelanoma skin cancers and 4,500 melanoma cases every year. In 2010, there were approximately 1.14 million skin cancer incidences in the United States alone. While the diagnosis and treatment of skin cancer at the early stages result in significantly greater chances of survival, currently available drug treatments are associated with high toxicity and poor response rates.
New analysis from Frost & Sullivan (http://www.pharma.frost.com) U.S. Skin Cancer Market finds that melanoma incidences accounted for 6.5 percent–approximately 73,599 cases–of skin cancer in the United States in 2010. This is expected to increase to approximately 116,466 incidences in 2017.
If you are interested in more information on this study, please send an e-mail to Britni Myers, Corporate Communications, at britni.myers@frost.com, with your full name, company name, title, telephone number, company e-mail address, company Web site, city, state and country.
"Only two approved drugs are available for melanoma," said Frost & Sullivan Industry Manager Jennifer Brice. "Both interferon alpha-2b and interleukin-2 (IL-2) are not completely effective and have a high degree of side effects, affecting patients’ quality of life."
Moreover, no FDA-approved drugs have been launched for melanoma for more than a decade. This has led to a high unmet need among skin cancer patients, especially those with melanoma. At present, patients are limited to taking chemotherapy (dacarbazine) and IL-2 (Proleukin). Neither treatment has shown to have any meaningful improvement in overall survival.
As a result, surgery is the most preferred form of treatment for early and high-risk skin cancer patients. Most skin cancers, including melanoma, can be effectively treated by removing the skin lesion and ensuring that the edges of the lesion are free from tumor cells. As tumors on the skin are easily detected, early skin cancer diagnosis has resulted in a reduced need for other forms of treatment.
However, new drug launches for melanoma treatment are expected in the near future. A few of the drugs in the pipeline have the potential to be blockbusters–especially for targeted therapies.
"Around 10 medications are expected to be launched during 2011 to 2017," said Brice. "One of them, Ipilimumab, has achieved primary endpoint of improvement in overall survival in previously untreated patients with metastatic melanoma."
While these novel cancer therapies command premium pricing and mean higher revenues for the drug companies, the patent expiry of a few major medications in the coming years will give way to generics. The patent for the key drug Intron-A has already expired.
"Although entry of generics could increase adoption rate and availability, it would drive down the prices and hence market revenues," said Brice. "Further, tight budgets from insurance companies restrict the use of novel therapies and encourage generics."
If adequate reimbursements are not available, patients may tend to choose biosimilars instead of expensive novel therapies. To counter this trend, pharmaceuticals and biotech companies must offer personalized therapies with the goal of administering the right drug at the right dose for each patient.
Technologies such as genomic and proteomic data profiling are likely to yield novel molecular markers that detect skin cancer progression. This is expected to generate significant opportunities for developing more effective therapies for skin cancer.
U.S. Skin Cancer Market is part of the Pharmaceuticals & Biotechnology Growth Partnership Services program, which also includes research in the following markets: Global Skin Cancer Therapeutics Market, U.S. Breast Cancer Therapeutics Market, and U.S. Colorectal Cancer Market. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.
Shes trading beautifully. Test the HOD again by EOD?
Is it just me or is the CBIS website bogged down by visitors atm
Maximum free trading (1/12/2012): 1,141,908,603
Bid size: 684,303,733
I would imagine iHub alone owns nearly the remaining 457,604,870
Someone wants all the shares as cheap as possible IMO.
ECOS bounce?
I guess you didn't pick up on my sarcasm :/. I am quite long on CBIS.
No big deal, just CBIS curing cancer LOL
lol I like the video. Definitely used a simpler version for forecasting growth than what is used on accounting exams :D. I think you get the gist though.
Very nice! Hoping for a solid Q4, which I think it will be :)
That was pretty funny. I bet it sent off some serious scanners lol
So I thought I would play with BFHJ #'s with some personal projections
Profit:
Q1 $52,812.00
Q2 $76,353.00
Q3 $116,449.33
Projected Q4 $147,157.02
Q1->Q2 44.57%
Q2->Q3 34.28%
Projected Q3->Q4 26.37%
Market cap (as of 1/12/2012)$415,124.70
Projected Net Income from 2011 $392,711.35
Projected EPS $.000189
Projected PE 1.06
Any thoughts?
1 British pound sterling = 1.5409 US dollars
Oh hello ECOS lol. Finally has a pulse :P
It is not a site that holds value, rather the marketing and brand recognition
It also appears this information doesn't exist on their website. At least I can't find it
http://www.beneficialholdings.info/
"The Company does not presently use any legal counsel
to advise on matters relating to operations,
business development, or disclosure" Per filing
"The Company utilizes the services of Luis Reyes as
its accountant in Nicaragua. Mr. Reyes’ business
address is care of our main address. His email
address is luis(at)beneficialholdings.info" Per filing
Is this the phone # and email you have?
Tel:
(505) 22682234
Email:
jsequeira@evaldiviap.com.ni
Nice :)
And while you're at it, check out PIPA as well :D
lol. Couldn't imagine a better analogy for CBIS!
All is going pretty well..although BFHJ has me feeling a little iffy. Starting to sketch me out :/. Would also enjoy some word on the CBIS dividend lol. I guess I'll have to keep my eye on the $ for this one. A chart between cotton and NADVF seems like it should be correlative, although not the entire causation for the price movement here. Hopefully the product does well @ target. Kind of bums me out they had to do flax > hemp. How have you been? Again, really appreciate the email you send out :D~.
Hmm I wonder if this will make its way back to $2.50.
Perhaps the co has to get it to $.10 in order for the new class to exist?
Some big stuff going on over here.
Long CBIS!!
LOL why even bother? :D
268 as of june 13, 2011
Haha I completely agree
They have $200,000 cash on hand. They are capable of doing a lot of things for the share price.
Sometimes takes me 4 hours to get filled at the ask. Shady stuff.
If it stays this low for long, I am buying my family BFHJ stock certificates as stocking stuffers :P
I wouldn't doubt a PR tomorrow from the company highlighting the $116,449 in net income from Q3 and the up listing. We should be seeing current status once they file Q4 in a timely manner as they have stated. Looking good from here on out!
Anyone know how much was left on the ask EOD?
For me there is nothing imperative about the share price rocketing up. If it does, awesome. If it doesn't, I can continue to accumulate cheap shares until it does. I can't even decide which I would prefer. All I know is another quarter of increased profits will be big in my book. These new gaming machines are also an exciting twist. The more events in the pipeline, the merrier. GLTY.
GM pump, great to see you over here!